Recursion rises on new data for asset for polyps

 

• Recursion Pharmaceuticals (RXRX) is up ~3% Monday after reporting phase 1b/2 data on REC-4881 for familial adenomatous polyposis.
• Participants in the placebo-controlled study who took the allosteric MEK1/2 inhibitor saw a 43% median reduction in polyps following 12 weeks of treatment and 75% experienced reductions in total polyp burden.
• In these patients, there was a 53% median reduction in polyps from baseline.
• Also, 40% of patients (4 out of 10) achieved a ≥1-point improvement in a measure of upper gastrointestinal disease severity.
• Familial adenomatous polyposis is an inherited genetic condition leading to the development of hundreds of thousands of noncancerous polyps in the colon and rectum.
• Recursion said that it expects to discuss a registration pathway for REC-4881 in H1 2026.

https://www.msn.com/en-us/money/markets/recursion-rises-on-new-data-for-asset-for-polyps/ar-AA1RX9Ir